Ivan Montoliu Roura

USPTO Granted Patents = 13 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 31)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 54(Granted Patents)

Company Filing History:

Societe Des Produits Nestle S.a.

Years Active: 2015-2020

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10648991 - Biomarkers for epicardial adipose tissue (2020-05-12),

2. 10094819 - Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity (2018-10-09),

3. 10036740 - Trimethylamine as a biomarker of prebiotic efficacy for weight gain prevention (2018-07-31),

4. 9817003 - 9-oxo-HODE as a biomarker for healthy aging (2017-11-14),

5. 9523671 - Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention (2016-12-20),

6. 9518975 - Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention (2016-12-13),

7. 9410963 - Hexanoylglycine as biomarker for the predisposition for weight gain and obesity (2016-08-09),

8. 9341615 - PC-O 40:1 as a biomarker for healthy aging (2016-05-17),

9. 9322821 - P-cresol sulphate as a biomarker for healthy aging (2016-04-26),

10. 9261521 - PC-O 42:4—a biomarker for visceral adiposity (2016-02-16),

11. 9261520 - PC-O 44:4—a biomarker for visceral adiposity (2016-02-16),

12. 9201081 - PC-O 44:6—a biomarker for visceral adiposity (2015-12-01),

13. 9201064 - Phenylacetylglutamine as a biomarker for healthy aging (2015-12-01),

Title: Ivan Montoliu Roura: A Pioneer in Biomarker Research

Introduction: Ivan Montoliu Roura, based in Lausanne, Switzerland, is an accomplished inventor with a notable portfolio of 13 patents. His work primarily focuses on the innovative use of biomarkers in the fields of nutrition and health, contributing significantly to our understanding of obesity and adipose tissue management.

Latest Patents: Among his latest inventions, Roura has developed a method for predicting the level of epicardial adipose tissue (EAT) in subjects. This method involves determining levels of various lipid biomarkers in a sample, including phosphatidylcholine (PC), diacylglycerol (DAG), and phosphatidylethanolamine-ether (PE-O). By comparing these levels to reference values, the method provides insights into the levels of EAT fat in the subject. Additionally, he has introduced trimethylamine-N-oxide as a biomarker for assessing predisposition to weight gain and obesity, enabling better dietary management strategies.

Career Highlights: Roura's career is marked by his contributions to renowned companies in the food and health sector, including Nestec S.A. and Société des Produits Nestlé S.A. His work has not only advanced scientific understanding but has also directed practical applications in nutrition that can impact public health.

Collaborations: Throughout his career, Roura has collaborated with esteemed colleagues such as Francois-Pierre Martin and Sebastiano Collino. These partnerships have fostered a collaborative research environment that spurs innovation and creativity in health and nutritional sciences.

Conclusion: Ivan Montoliu Roura stands out as a leading inventor whose dedication to biomarker research has led to significant advancements in understanding obesity and related health issues. His innovative patents continue to influence the fields of nutrition and health, showcasing the impact of dedicated research and invention in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.